Related Experiment Video

Updated: May 25, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway

Gen Lin1, Zhiwei Tang, Yun-Bin Ye

  • 1Graduate School of Education, Fujian Medical University, and Department of Medical Oncology, Union Hospital, Fuzhou, PR China.

Oncology Reports
|February 14, 2012
PubMed

Insights

Investigating KRAS and NF-κB in colorectal cancer revealed that KRAS knockdown reduces NF-κB activation. Tumors with KRAS mutations and active NF-κB show significantly poorer patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The interplay between KRAS mutations and NF-κB signaling in colorectal cancer (CRC) remains incompletely understood.
  • KRAS is a key oncogene, and NF-κB is a critical transcription factor involved in inflammation and cancer progression.

Purpose of the Study:

  • To elucidate the relationship between KRAS and NF-κB signaling pathways in colorectal cancer.
  • To determine the impact of KRAS status on NF-κB activation and its correlation with patient prognosis in CRC.

Main Methods:

  • Western blotting was employed to assess protein expression changes in SW620 cells following KRAS knockdown.
  • Immunohistochemistry and statistical analysis were used to evaluate KRAS status, NF-κB activation, and overall survival in 167 CRC tumor tissues.

Main Results:

  • KRAS knockdown in SW620 cells led to decreased expression of RAS, p-ERK, p-IκBα, and p65, indicating reduced NF-κB pathway activity.
  • MEK inhibitor U0126 also downregulated p-ERK, p-IκBα, and p65, suggesting a role for the ERK pathway.
  • Tumors with KRAS mutations exhibited significantly higher NF-κB p65 activation (50.8%) compared to wild-type KRAS tumors (30.6%).
  • Patients with both KRAS mutations and activated NF-κB had a poorer overall survival (median 28.4 months) compared to other tumor types.

Conclusions:

  • NF-κB activation is reduced in KRAS-knockdown cells, potentially through the RAS-ERK-IκBα pathway.
  • The co-occurrence of KRAS mutations and activated NF-κB in colorectal cancer signifies a poor prognosis for patients.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...